The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Plitican     6-methoxy-N-[(1-prop-2- enylpyrrolidin-2...

Synonyms: Limican, Litican, Liticum, Superan, Vergentan, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Alizapride

 

High impact information on Alizapride

 

Chemical compound and disease context of Alizapride

 

Biological context of Alizapride

 

Anatomical context of Alizapride

 

Associations of Alizapride with other chemical compounds

 

Gene context of Alizapride

 

Analytical, diagnostic and therapeutic context of Alizapride

References

  1. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Joss, R.A., Galeazzi, R.L., Bischoff, A.K., Pirovino, M., Ryssel, H.J., Brunner, K.W. Clin. Pharmacol. Ther. (1986) [Pubmed]
  2. Antiemetic efficacy of escalating doses of alizapride against chemotherapy-induced emesis. Abad-Esteve, A., Rosell, R., Moreno, I., Serichol, M., Moya, L., Ribas-Mundo, M. Oncology (1989) [Pubmed]
  3. Effect of intravenous alizapride on spinal morphine-induced pruritus. Horta, M.L., Vianna, P.T. British journal of anaesthesia. (2003) [Pubmed]
  4. High-dose alizapride versus high-dose domperidone: a double-blind comparative study in the management of cis-platinum-induced emesis. Huys, J., Troch, M., Bourguignon, R.P., Smets, P. Current medical research and opinion. (1985) [Pubmed]
  5. Alizapride in the prevention of postoperative vomiting. A double-blind comparison. Vanacker, B., Van Aken, H. Acta anaesthesiologica Belgica. (1988) [Pubmed]
  6. Does dexamethasone enhance the efficacy of alizapride in cis-platinum-induced delayed vomiting and nausea? Münstedt, K., Wunderlich, I., Blauth-Eckmeyer, E., Zygmunt, M., Vahrson, H. Oncology (1998) [Pubmed]
  7. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group. Clavel, M., Bonneterre, J., d'Allens, H., Paillarse, J.M. Eur. J. Cancer (1995) [Pubmed]
  8. A comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin-induced emesis. The French Pneumology Group for the Ondansetron Study. Depierre, A., Lebeau, B., d'Allens, H. Oncology (1992) [Pubmed]
  9. The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study. Molino, A., Guglielmo, L., Azzolini, M.E., Biondani, P., Capelli, M.C., Grandinetti, A., Griso, C., Martinelli, G., Martini, N., Zanotti, R. Oncology (1991) [Pubmed]
  10. High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study. Giaccone, G., Bertetto, O., Secat, M.A., Calciati, A. Oncology (1988) [Pubmed]
  11. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Lee, C.R., Plosker, G.L., McTavish, D. Drugs (1993) [Pubmed]
  12. Study of the prophylactic effect of droperidol, alizapride, propofol and promethazine on spinal morphine-induced pruritus. Horta, M.L., Morejon, L.C., da Cruz, A.W., Dos Santos, G.R., Welling, L.C., Terhorst, L., Costa, R.C., Alam, R.U. British journal of anaesthesia. (2006) [Pubmed]
  13. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Bleiberg, H., Gerard, B., Dalesio, O., Crespeigne, N., Rozencweig, M. Cancer Chemother. Pharmacol. (1988) [Pubmed]
  14. Absolute intramuscular, oral, and rectal bioavailability of alizapride. Houin, G., Barre, J., Tillement, J.P. Journal of pharmaceutical sciences. (1984) [Pubmed]
  15. Pharmacokinetics of alizapride in children receiving chemotherapy for solid tumour. Rey, E., Stettler, E., D'athis, P., Pons, G. Fundamental & clinical pharmacology. (2001) [Pubmed]
  16. Manometric study of the activity of alizapride on the motor function of the human sphincter of Oddi. Warzee, P.L., Dive, C.C. Journal of clinical pharmacy and therapeutics. (1988) [Pubmed]
  17. Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study. Seng, K.T., Tiong, C.E., Hiang, T.C. British journal of clinical pharmacology. (1994) [Pubmed]
  18. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. Chivers, J.K., Gommeren, W., Leysen, J.E., Jenner, P., Marsden, C.D. J. Pharm. Pharmacol. (1988) [Pubmed]
  19. Quantitative determination of alizapride in human plasma by high-performance liquid chromatography. Coulais, Y., Campistron, G., Caillard, C., Houin, G. J. Chromatogr. (1986) [Pubmed]
 
WikiGenes - Universities